Soleno Therapeutics Inc

Neurocrine Biosciences acquires Soleno Therapeutics, boosting rare‑disease innovation while keeping staff and operations intact for a seamless transition.

Soleno Therapeutics faces a securities‑fraud class action over its hyperphagia drug launch, urging shareholders to file claims by May 5, 2026 and weigh potential losses and company impact.

Soleno Therapeutics faces multiple securities‑law investigations while launching a $100 million share‑repurchase, a move that spurred a short‑term stock rally amid growing regulatory scrutiny.

Soleno Therapeutics Inc. has reported a significant increase in revenue and a positive financial performance in Q2, driven by the successful launch of its flagship product VYKAT XR.

Soleno Therapeutics has successfully priced a $200 million public offering to support the launch of its key product VYKAT XR, a rare disease treatment.